Scialytics: IHU spin-off builds first AI powered end-to-end ecosystem to measure and reduce surgical risk

3 Sep, 2025

Temps de lecture : ( Nombre de mots : )

Every year, millions of patients worldwide face preventable surgical complications, ranging from bleeding to infections, that extend recovery times, increase healthcare costs, and in some cases, put lives at risk. Despite advances in surgical techniques, hospitals still lack real-time tools to measure and reduce risk during operations.

Scialytics, a spin-off of the IHU Strasbourg, is tackling this challenge head-on, d. Drawing on more than a decade of cutting-edge research in surgical AI within the CAMMA research group, a joint IHU – University of Strasbourg lab led by Prof. Nicolas Padoy, one of the world’s leading figures in surgical data science and CSO of IHU Strasbourg.

Having benefited from BPI France FrenchTech financing, and maturation through the regional Quest for Health start-up incubator, the company has developed the world’s first AI-powered ecosystem end-to-end designed to analyze surgical video in real time, supporting surgeons during critical steps and enabling data-driven quality assurance across healthcare systems.

AI-Augmented Laparoscopic Cholesystectomy

With backgrounds shaped in the IHU Strasbourg’s unique multidisciplinary and highly connected environment, the founding team brings together complementary expertise in data science, engineering, and surgery to translate over a decade of research into practical innovation that raises clinical standards:

  • Deepak Alapatt, MSc – CEO
  • Dr Pietro Mascagni, MD, PhD – Chief Medical Officer
  • Dr Luca Sestini, PhD – Chief Technology Officer
  • Dr Tong Yu, PhD – Head of Product
  • Prof. Nicolas Padoy – Scientific Advisor

2025 Milestones: From Lab to OR

Scialytics has already achieved key regulatory and clinical milestones:

  • FDA feedback confirmed a streamlined approval pathway for its first software-as-a-medical-device product: a real-time assistant for laparoscopic cholecystectomy (gallbladder removal).
  • Clinical validation is underway:
    • A first-in-human study at IHU Strasbourg led by Prof. Silvana Perretta.
    • A U.S. comparative trial at UCSF, led by Prof. Adnan Alseidi.
    •  

An Open Ecosystem for Surgical Innovation

Scialytics is actively seeking collaborations with:

  • Surgeons and hospitals aiming to raise safety and quality standards.
  • Investors looking for clinically validated healthtech with clear regulatory pathways.
  • Digital health innovators building complementary solutions in surgery, femtech, and biotech.

For more information or partnership opportunities, visit scialytics.io.

Scialytics is yet another example of the ability of IHU Strasbourg — where clinicians, engineers and researchers work side by side — to transform pioneering research of excellence into a concrete solution that benefits patients and fosters business creation.

À LA UNE